Press
Releases
Press Releases
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 27, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will present new preclinical data on novel assays used to evaluate lentiviral vector
Sep 27, 2022
AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis
Second AVROBIO gene therapy program that has been granted rare pediatric disease designation by FDA AVR-RD-04 has previously received orphan drug designation from FDA and EMA CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 20, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy
Sep 20, 2022
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial
First in-human pediatric Phase 1/2 study to evaluate the safety and tolerability of first-in-class gene therapy targeting infants age ≥3 months and ≤12 months, diagnosed with nMPS-II University of Manchester ( U.K. ) expects to initiate clinical trial later this year U.S.
Sep 14, 2022
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 8, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 58,000 restricted stock units (RSUs) to three new
Sep 08, 2022
AVROBIO to Participate in Four Upcoming Investor Conferences in September
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 31, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming
Aug 31, 2022
AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update
Presented positive data from first five patients in Phase 1/2 cystinosis trial 1 showing systemic gene therapy effect at the American Society of Gene and Cell Therapy Annual Meeting; all five patients remain off oral cysteamine Comprehensive Gaucher disease franchise update planned for Q4 2022
Aug 09, 2022
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 4, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 35,500 restricted stock units (RSUs)
Aug 04, 2022
AVROBIO to Participate in Two Upcoming Investor Conferences in August
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two
Aug 01, 2022
AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
AVR-RD-05 is the fourth AVROBIO gene therapy to receive orphan drug designation FDA previously granted rare pediatric disease designation for AVR-RD-05 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 13, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared
Jul 13, 2022
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 6, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 37,500 restricted stock units (RSUs)
Jul 06, 2022
Displaying 1 - 10 of 27